Association between germline BRCA1 pathogenic variants and uterine serous carcinoma among women with breast cancer: a population-based analysis - 11/11/25
Doi : 10.1016/j.ajog.2025.10.009
Roni Nitecki Wilke, MD, MPH 
, Nuria Agusti, MD
, Nuria Agusti, MD Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Nuria Agusti, MD
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Austin, TX
Chi-Fang Wu, PhD, MD
Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Chi-Fang, TX
Maria D. Iniesta, MD, PhD
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Austin, TX
William B. Manning, MD
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology Massachusetts General Hospital, Boston, MA
David Viveros-Carreno, MD
Unidad Ginecología Oncológica, Grupo de Investigación GIGA, Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC), Bogotá, Colombia
Clínica Universitaria Colombia, Grupo de Investigación Salud de la mujer Sanitas, Bogotá, Colombia
Allison W. Kurian, MD, MSc
Departments of Medicine and of Epidemiology and Population Health, Stanford University, Stanford, CA
J. Alejandro Rauh-Hain, MD, MPH
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Chi-Fang, TX
Alexander Melamed, MD, MPH
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology Massachusetts General Hospital, Boston, MA
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Tuesday 11 November 2025
Plan
| The authors report no conflict of interest. |
|
| J.A.R.-H. and A.M. contributed equally to this work. |
|
| Funding for this study was supported by grants from the National Institutes of Health National Cancer Institute (NIH/NCI) under Cancer Center Support Grant number P30 CA016672 (J.A.R.-H., R.N.W., M.D.I., and C.-F.W.), grant number K08 CA234333 (J.A.R.-H.), and by the Fundación Alfonso Martin Escudero (N.A.) and Department of Defense Ovarian Cancer Research Program grant number OC210024 (A.M.). The funding sources were not involved in the development of the research hypothesis or study design, data analysis, or manuscript writing. |
|
| The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries, under cooperative agreement 1NU58DP007156; and the National Cancer Institute's Surveillance, Epidemiology, and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the authors and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their contractors and subcontractors. |
© 2025
Elsevier Inc. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?